Real-life experience with Hydroxyurea (cas 127-07-1) in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent
-
Add time:09/29/2019 Source:sciencedirect.com
We conducted the first nation-wide cohort study of sickle cell disease (SCD) in Italy, a Southern European country exposed to intense recent flux migration from endemic areas for SCD. We evaluate the impact of Hydroxyurea (cas 127-07-1) on a total of 652 pediatric and adult patients from 33 Reference Centers for SCD (mean age 24.5 ± 15 years, 51.4% males). Hydroxyurea median treatment duration was 7 years (range: < 1 year to 29 years) at a mean therapeutic dose of 18 ± 4.7 mg/kg/day. Hydroxyurea was associated with a significant increase in mean total and fetal hemoglobin and a significant decrease in mean hemoglobin S, white blood and platelet counts, and lactate dehydrogenase levels. Hydroxyurea was associated with a significant reduction in the incidence of acute chest syndrome (− 29.3%, p < 0.001), vaso-occlusive crisis (− 34.1%, p < 0.001), hospitalization (− 53.2%, p < 0.001), and bone necrosis (− 6.9%, p < 0.001). New silent cerebral infarction (SCI) occurred during treatment (+ 42.4%, p < 0.001) but not stroke (+ 0.5%, p = 0.572). These observations were generally consistent upon stratification for age, descent (Caucasian or African), genotype (βS/βS, βS/β0 or βS/β+) and duration of treatment (< or ≥ 10 years). There were no new safety concerns observed compared to those commonly reported in the literature. Our study, conducted on a large population of patients with different descent and compound state supports the benefits of hydroxyurea therapy as a treatment option. Registered at clinical trials.gov (NCT02709681).
We also recommend Trading Suppliers and Manufacturers of Hydroxyurea (cas 127-07-1). Pls Click Website Link as below: cas 127-07-1 suppliers
Prev:Case StudyMalleolar Ulceration Induced by Hydroxyurea (cas 127-07-1) Therapy for Chronic Eosinophila
Next:Clinical studyCutaneous ulcers associated with Hydroxyurea (cas 127-07-1) therapy) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Clinical studyCutaneous ulcers associated with Hydroxyurea (cas 127-07-1) therapy09/30/2019
- Case StudyMalleolar Ulceration Induced by Hydroxyurea (cas 127-07-1) Therapy for Chronic Eosinophila09/28/2019
- Acute Hydroxyurea (cas 127-07-1) treatment reduces tubular damage following bilateral ischemia-reperfusion injury in a mouse model of sickle cell disease10/01/2019
- Optimising genetic transformation of Trypanosoma cruzi using Hydroxyurea (cas 127-07-1)-induced cell-cycle synchronisation09/27/2019
- p53 mediates Hydroxyurea (cas 127-07-1) resistance in aneuploid cells of colon cancer09/26/2019
- Hydroxyurea (cas 127-07-1): Analytical techniques and quantitative analysis09/25/2019
- Hydroxyurea (cas 127-07-1) embryotoxicity is enhanced in P53-deficient mice09/24/2019
- Beliefs about Hydroxyurea (cas 127-07-1) in youth with sickle cell disease09/10/2019
- Original ArticlesTargeted Hydroxyurea (cas 127-07-1) Education after an Emergency Department Visit Increases Hydroxyurea (cas 127-07-1) Use in Children with Sickle Cell Anemia09/09/2019